Evidence map›Paper›PMID 30035180›Full record

ArticleOncoscience2018

Using interferon-beta to combat cancer stem cell properties in triple negative breast cancer.

Mary R Doherty, Mark W Jackson

Open access · diamondAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mary R DohertyDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; bCase Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Mark W JacksonDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA; bCase Comprehensive Cancer Center, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Case Comprehensive Cancer CenterUniversity School · US

Funding

TELOMERASE INACTIVATION BY RNASE L SIGNALS CELL DEATHP01CA062220 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, XIAOXIA, STARK, GEORGE ROBERT · 1994 to 2020
$35.6M
RESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5M
Interferon-beta inhibits the expansion of cancer stem-cellsR21CA198808 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W., STARK, GEORGE ROBERT · 2016 to 2017
$379k
NCI NIH HHS P01 CA062220NCI NIH HHS R21 CA198808NCI NIH HHS T32 CA059366
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer stem cellscellular plasticityinterferon-betatriple-negative breast cancer

Identifiers

PMID30035180
PMCPMC6049314
OpenAlexW2908305985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.